LITIGATION RESULTING FROM NAS-NRC REVIEW AND FDA DEMANDS FOR NEW DRUG STATUS

被引：0
|
作者：
TEMKO, SL [1 ]
机构：
[1] COVINGTON & BURLING,WASHINGTON,DC
来源：
FOOD DRUG COSMETIC LAW JOURNAL | 1971年 / 26卷 / 10期
关键词：
D O I：
暂无
中图分类号：
D9 [法律]; DF [法律];
学科分类号：
0301 ;
摘要：
引用
收藏
页码：464 / 471
页数：8
相关论文
共 50 条
  • [31] Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA-Sponsor Conferences
    Joseph A. DiMasi
    Michael Manocchia
    Drug information journal : DIJ / Drug Information Association, 1997, 31 (3): : 771 - 788
  • [32] Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review
    Brown, Beatrice L.
    Mitra-Majumdar, Mayookha
    Joyce, Krysten
    Ross, Murray
    Pham, Catherine
    Darrow, Jonathan J.
    Avorn, Jerry
    Kesselheim, Aaron S.
    JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022, 47 (06) : 649 - 672
  • [33] Early Entrant Protection in Approval Regulation: Theory and Evidence from FDA Drug Review
    Carpenter, Daniel
    Moffitt, Susan I.
    Moore, Colin D.
    Rynbrandt, Ryan T.
    Ting, Michael M.
    Yohai, Ian
    Zucker, Evan James
    JOURNAL OF LAW ECONOMICS & ORGANIZATION, 2010, 26 (03): : 515 - 545
  • [34] An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending
    Vernon, John A.
    Golec, Joseph H.
    Lutter, Randall
    Nardinelli, Clark
    QUARTERLY REVIEW OF ECONOMICS AND FINANCE, 2009, 49 (04): : 1260 - 1274
  • [35] Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
    Rodney Rouse
    Naomi Kruhlak
    James Weaver
    Keith Burkhart
    Vikram Patel
    David G. Strauss
    Therapeutic Innovation & Regulatory Science, 2018, 52 : 244 - 255
  • [36] Initiatives to speed new drug development and regulatory review: The impact of FDA-sponsor conferences.
    DiMasi, JA
    Manocchia, M
    Lasagna, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PII13 - PII13
  • [37] Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science
    Rouse, Rodney
    Kruhlak, Naomi
    Weaver, James
    Burkhart, Keith
    Patel, Vikram
    Strauss, David G.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (02) : 244 - 255
  • [38] A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA From 2007–2013
    Gunter F. Egger
    Gerold T. Wharton
    Suzanne Malli
    Jean Temeck
    M. Dianne Murphy
    Paolo Tomasi
    Therapeutic Innovation & Regulatory Science, 2016, 50 : 639 - 647
  • [39] REGEN-COV and COVID-19, update on the drug profile and FDA status: A mini-review and bibliometric study
    Mawazi, Saeid Mezail
    Khan, Jiyauddin
    Othman, Noordin
    Alolayan, Sultan Othman
    Alahmadi, Yaser M.
    Al Thagfan, Sultan S.
    Helmy, Sally A.
    Marzo, Roy Rillera
    JOURNAL OF PUBLIC HEALTH RESEARCH, 2021, 10
  • [40] Green Light from the FDA for New Drug Development in Irritable Bowel Syndrome and Functional Dyspepsia
    Talley, Nicholas J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (06): : 1339 - 1341
12345